Insider Buying: Immunome, Inc. (NASDAQ:IMNM) CTO Purchases $103,566.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai acquired 12,300 shares of Immunome stock in a transaction that occurred on Monday, March 24th. The shares were purchased at an average price of $8.42 per share, with a total value of $103,566.00. Following the purchase, the chief technology officer now owns 33,300 shares in the company, valued at $280,386. This represents a 58.57 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Immunome Price Performance

Shares of IMNM stock opened at $7.28 on Friday. The business has a fifty day moving average of $9.56 and a 200 day moving average of $11.38. The firm has a market capitalization of $633.00 million, a price-to-earnings ratio of -0.90 and a beta of 1.93. Immunome, Inc. has a 1 year low of $6.94 and a 1 year high of $25.75.

Immunome (NASDAQ:IMNM) last released its earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. As a group, equities research analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current year.

Institutional Trading of Immunome

Institutional investors and hedge funds have recently bought and sold shares of the business. Enavate Sciences GP LLC purchased a new position in shares of Immunome during the fourth quarter worth $36,939,000. JPMorgan Chase & Co. grew its position in Immunome by 2,540.4% during the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock worth $6,888,000 after purchasing an additional 624,045 shares during the period. Janus Henderson Group PLC raised its stake in shares of Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after buying an additional 324,614 shares during the last quarter. Granahan Investment Management LLC acquired a new position in shares of Immunome in the 4th quarter valued at about $3,337,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Immunome by 2,696.5% in the fourth quarter. Renaissance Technologies LLC now owns 316,000 shares of the company’s stock worth $3,356,000 after buying an additional 304,700 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on IMNM shares. Stephens reaffirmed an “overweight” rating and issued a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Wedbush restated an “outperform” rating and set a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Lifesci Capital began coverage on Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target for the company. Finally, Guggenheim lowered their price target on Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, March 20th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $25.50.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.